“Science has a meaning if it is understood as a way to the truth and the truth as the good of people.”
We would like to introduce the latest ESMO guide for patients BONE SARCOMA.
Bone sarcomas are rare tumours, accounting for less than 1 % of malignant tumours. They may originate in any part of the body where are bones, i.e. skull, limbs and girdles, the spine and ribs. Currently, i tis not clear why bone sarcomas occur. The management of the different types of bone sarcomas also varies according to the type.
More information
An initial meeting took place in Lisbon at the beginning of May and launched an international cooperation on an important ECHoS project.
The goal of the project is to create national Cancer Mission Hubs in every EU country within the new European consortium.
Slovakia is represented in the project by the National Oncology Institute, part of National Cancer Institute, and Cancer Research Foundation.
More information
Europe is a continent with the highest number of annually diagnosed cases of melanoma skin cancer. Each year, over 150,000 cases of melanoma are diagnosed in Europe. This is expected to rise to over 170,000 million cases annually by 2040. Slovakia ranks 25th according to the number of melanomas diagnosed annually, which is not something to be proud of.
More information
An expert conference PATIENT-ORIENTED SCIENTIFIC RESEARCH CONTINUUM organized by Cancer Research Foundation and NOI took place on 7 March 2023.
The main topic was cancer research, possibilities of active participation and updates on EU Mission: Cancer.
More information
We present to you our annual publication about the state of oncology in Slovakia which focuses on clinical, radiation, hematological, pediatric, geriatric and palliative oncology.
It maps out the activities of oncological societies and cooperative groups, activities in the area of experimental oncology and activities of NOI. It also includes the Report of the Institute of Research and Development of the MoH SR about the implementation of NOP objectives and vision for 2022.
More information